Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN

Allspring Global Investments Holdings LLC lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 8.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 201,832 shares of the company’s stock after selling 19,629 shares during the period. Allspring Global Investments Holdings LLC owned 0.37% of LivaNova worth $12,419,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock worth $1,394,000 after purchasing an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after buying an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after buying an additional 15,405 shares during the last quarter. Intech Investment Management LLC grew its position in shares of LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after buying an additional 7,195 shares during the last quarter. Finally, Strs Ohio acquired a new stake in LivaNova during the 1st quarter worth $130,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of LIVN opened at $63.79 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.16 and a current ratio of 1.36. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $71.92. The firm has a 50-day simple moving average of $64.94 and a 200-day simple moving average of $60.44. The company has a market capitalization of $3.49 billion, a price-to-earnings ratio of -14.30 and a beta of 0.97.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.06. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm had revenue of $360.92 million for the quarter, compared to analysts’ expectations of $354.31 million. During the same quarter in the previous year, the firm posted $0.81 EPS. The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, equities research analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

LIVN has been the subject of a number of research reports. Barclays boosted their price target on shares of LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. KeyCorp assumed coverage on LivaNova in a research report on Friday, December 19th. They set an “overweight” rating and a $81.00 target price on the stock. Piper Sandler reissued an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Mizuho upped their target price on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, Stifel Nicolaus set a $80.00 price target on LivaNova in a research note on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and an average price target of $74.78.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.